Renal-Cell Carcinoma

In a phase 3 study, adjuvant pembrolizumab after nephrectomy improved disease-free survival versus placebo in patients with high-risk disease. Read More ›

Belzutifan, an oral, novel hypoxia-inducible factor (HIF)-2α inhibitor, showed encouraging activity as a single agent in heavily pretreated patients with advanced clear-cell renal-cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, as well as impressive tumor shrinkage when used in combination with cabozantinib (Cabometyx) in separate studies presented at the 2021 ASCO Genitourinary Cancers Symposium. Read More ›

The combination of nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to show superior survival outcomes compared with single-agent sunitinib (Sutent) as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to extended follow-up data from the phase 3 CheckMate-9ER clinical trial presented at the 2021 ASCO Genitourinary Cancers Symposium. Read More ›

In a keynote address during the virtual 2020 International Kidney Cancer Symposium, William G. Kaelin, Jr, MD, Sidney Farber Professor of Medicine, Dana-Farber Cancer Institute, Boston, MA, provided an update on treatment strategies aimed at improving outcomes for patients with clear-cell renal-cell carcinoma (RCC) caused by inactivation of the VHL gene. Promising therapies include immunotherapies, hypoxia-inducible factor (HIF)-2α inhibitors, and cyclin-dependent kinase (CDK)4/6 inhibitors. Read More ›

The treatment of renal-cell carcinoma (RCC) continues to evolve with the development of more effective frontline regimens. During the virtual 2020 International Kidney Cancer Symposium, experts discussed the expanding role of several of these therapies, including tyrosine kinase inhibitors (TKIs) and immunotherapies, which are being evaluated in various combinations to improve outcomes for patients with advanced and high-risk disease. Read More ›

There has been an increased focus on the study of tumor alterations that may predict treatment benefit or serve as possible actionable targets in cancer. Read More ›

First-line therapy with pembrolizumab (Keytruda) plus ­axitinib (Inlyta) significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates compared with standard-of-care sunitinib (Sutent) in patients with clear-cell metastatic renal-cell carcinoma (RCC) in KEYNOTE-426. The combination of pembrolizumab plus axitinib achieved a significant 47% reduction in mortality risk versus sunitinib (P <.0001). Read More ›

Read More ›